TrialNature medicine2023

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Farshad Nassiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.